After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
|Articles|September 24, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related to this article
Emma Halligan found connection at a free New Jersey retreat for women with cancer, which held its annual walk and 5K on Oct. 17.
Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.
U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.
Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter explains why getting a second opinion changed the course of her care.
Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.
Noah Elliott, now a Paralympic snowboarder, counted small wins during inpatient chemotherapy and found inspiration in the youngest children on his hospital floor.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Advertisement
Advertisement
Trending on CURE
1
New Myelofibrosis Guidelines Back Wider Gene Testing at Diagnosis
2
FDA Approves Jemperli for dMMR Locally Advanced Rectal Cancer
3
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
4
Why Cancer Screening Remains Important for Long-Term Cancer Survivors
5